Shanghai Duomirui Biotechnology

Shanghai Duomirui Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of targeted small molecule therapies for cancer. The company's primary focus is on the PI3K signaling pathway, which plays a critical role in cell growth and survival. Its lead candidate, DMR-2573, is a potent and selective PI3K inhibitor currently in Phase 1/2 clinical trials for advanced solid tumors and hematological malignancies. Duomirui aims to develop highly selective inhibitors that offer improved safety and efficacy profiles compared to existing treatments. The firm leverages its internal R&D capabilities to advance a pipeline of innovative oncology drugs. The company is backed by leading healthcare investors including HighLight Capital and Qiming Venture Partners.